NRXP
NRx Pharmaceuticals, Inc.
1W: -0.5%
1M: +0.5%
3M: -18.9%
YTD: -29.4%
1Y: -15.1%
3Y: -72.8%
5Y: -99.3%
$1.85
+0.01 (+0.54%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$32.0M
52W Range1.58-3.84
Volume642,170
Avg Volume998,884
Beta1.99
Dividend—
Analyst Ratings
Company Info
CEOJonathan C. Javitt
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-04
Websitenrxpharma.com
1201 Orange Street
Wilmington, DE 19801
US
Wilmington, DE 19801
US
484 254 6134
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Latest News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Casper Joseph Michae | A-Award | 100,000 | $2.39 | 2026-01-27 |
| Casper Joseph Michae | 100,000 | $2.39 | 2026-01-27 | |
| B Group, Inc. | 0 | — | 2025-08-18 | |
| Javitt Jonathan C | A-Award | 125,000 | $1.73 | 2025-04-09 |
| McBride Dennis | A-Award | 25,000 | $1.73 | 2025-04-09 |